Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 9Phase 1/2 3Phase 3 2Phase EARLY_PHASE1 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 6Genitourinary 4Gastrointestinal 3Breast 3Thoracic 2Other solid neoplasm 2Tumor-Agnostic 1Head & Neck 1CNS 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Trastuzumab 72Paclitaxel 63Cyclophosphamide 56pembrolizumab 52Fulvestrant 42Carboplatin 39Capecitabine 37Docetaxel 32Letrozole 27Doxorubicin 23palbociclib 21pertuzumab 20Nivolumab 18eribulin 17abemaciclib 17ribociclib 16Gemcitabine 16130-nm albumin-bound paclitaxel 16durvalumab 15Everolimus 15Albumin-Bound Paclitaxel 15sacituzumab govitecan 14Lapatinib 14Filgrastim 14fludarabine 13exemestane 13Taxes 13Bevacizumab 13Cisplatin 12olaparib 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × niraparib × Breast × Clear all
NCT03368729 2026-01-23

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

University of Alabama at Birmingham

Phase 1/2 Active not recruiting
46 enrolled
Breast

Breast Neoplasms

NCT02657889 2022-12-01

TOPACIO

Tesaro, Inc.

Phase 1/2 Completed
122 enrolled 29 charts
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04655183 2021-06-30

Study of M4344 in Combination With Niraparib

EMD Serono

Phase 1/2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡